Project Grant R01AI196080
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $279,000 Project Grant to the La Jolla Institute for Immunology from April 1, 2026, through March 31, 2028, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award funds detailed analysis of antibody repertoires in multiply-exposed individuals from the Democratic Republic of the Congo who demonstrate extraordinarily broad humoral immune responses against multiple...
- Federal Project Grant Award Summary The La Jolla Institute for Immunology received a $890,877 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026, through January 31, 2031. This five-year research initiative focuses on elucidating the immunoregulatory mechanisms of Interleukin-1 Receptor 8 (IL-1R8) and developing novel therapeutic strategies targeting this...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $566,875 to the La Jolla Institute for Immunology under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 18, 2026, with a completion date of January 31, 2028. Under this Project Grant, the institute will conduct research to de-orphanize a novel G-protein coupled receptor (GPCR) expressed by tissue-resident memory T cells (TRM cells). The research objective...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Applied Biomedical Science Institute a Project Grant of $976,318 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 6, 2026, with a project completion date of March 31, 2031. The award funds research to elucidate the molecular mechanisms underlying the cow immune system's production of ultralong complementarity-determining region H3 (CDR H3) antibodies—a unique...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $626,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The funding will support research to explore the dependence of arenaviruses on the metabolism of the monosaccharides D-glucose and D-mannose, with the goal of developing carbohydrate antimetabolite compounds as potential pan-arenavirus therapeutics. Specifically,...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $159,300 Project Grant on April 2, 2026, to the La Jolla Institute for Immunology to investigate human upper airway immune memory kinetics and durability against respiratory pathogens under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research project, which will conclude on March 31, 2031, develops and applies novel methodologies for longitudinal sampling of...
- Federal Grant Award Summary The La Jolla Institute for Immunology received a $764,868 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2031. This award supports investigator-initiated biomedical research examining house dust mite (HDM) allergen-specific T cell subsets in allergic disease and asthma. The research focuses on...
The La Jolla Institute for Immunology received a $923,708 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with a completion date of March 31, 2031. This five-year research initiative focuses on developing a therapeutic monoclonal antibody (MAB) cocktail targeting New World Arenaviruses (NWAs), including Machupo and Junin viruses, which cause hemorrhagic fever. The project addresses a critical gap in available therapeutics, as currently no licensed arenavirus treatments exist despite the significant public health threat posed by these pathogens. The research will employ advanced structural biology techniques, including high-resolution cryo-electron microscopy, to characterize prefusion-stabilized NWA glycoproteins and elucidate antibody-antigen interactions at the molecular level. The institute will isolate broadly protective neutralizing antibodies from immunized animal models and humans vaccinated with Candid #1, assess their breadth and potency, and identify candidates for therapeutic development. These research outputs are intended to generate novel broadly applicable therapeutics for arenavirus infections, building on the team's prior discoveries regarding vulnerable epitopes on Lassa virus surface glycoproteins.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $923.7k | 4/1/26 |